Skip to content

BMC cancer

ISSN 1471-2407

3 papers in the library · 10 citations · publishing 2024-2025

Papers

Alleviating role of ketamine in breast cancer cell-induced osteoclastogenesis and tumor bone metastasis-induced bone cancer pain through an SRC/EGR1/CST6 axis.

BMC cancer December 18, 2024 Xiaomin Zhang, Yanmei Zhang, Wei Du 5 citations

Ketamine suppresses breast cancer cell growth, spread, and the ability of those cells to promote bone-destroying osteoclast activity. In cell lines and a mouse model of bone metastasis, ketamine reduced tumor burden and pain. The drug works by inhibiting the SRC protein, which in turn restores the EGR1/CST6 signaling pathway. Overexpression of SRC blocked ketamine's effects, while restoring EGR1 or CST6 counteracted SRC's harmful actions. The findings indicate that ketamine alleviates bone metastasis and associated pain in breast cancer through this molecular mechanism.

A feasibility study of a tailored mindfulness-based group intervention for psychological distress and adjustment for allogeneic hematopoietic stem cell transplant outpatients.

BMC cancer July 14, 2025 Litza Kiropoulos, Phuong Linh Dang, Vanja Rozenblat 3 citations

A six-week group-based mindfulness intervention was feasible and accepted by patients who had undergone allogeneic hematopoietic stem cell transplantation for hematologic cancer. After the intervention, the 13 participants who completed the program reported significant decreases in anxious preoccupation about cancer and in physical functioning, along with a significant increase in perceived functional wellbeing. Large effect sizes were observed for the reductions in anxious preoccupation. Qualitative feedback highlighted that participants valued the social support from the group format and suggested offering the intervention both before and after transplant.

A randomised study to evaluate the potential added value of shared meditation involving people with cancer, health professionals and third persons compared to meditation conducted with patients only: design of the Implic-2 protocol.

BMC cancer September 4, 2024 Virginie Prevost, Titi Tran, Alexandra Leconte et al. 2 citations

A two-arm randomised trial will test whether adding shared meditation sessions that include cancer patients, health professionals, and third parties improves well-being more than meditation limited to patients alone. The study plans to enroll 96 participants: 64 patients, 16 health professionals, and 16 third persons. Patients in the experimental arm will meditate in mixed groups, while those in the control arm will meditate in patient-only groups. Outcomes include quality of life, perceived stress, self-efficacy, mindfulness, self-compassion, and carer burnout. A qualitative focus-group component will help optimize future implementation.